Stock ANIK ANIKA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
26.49 USD +2.32% Intraday chart for Anika Therapeutics, Inc. +2.28% +16.90%
14/03 Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
13/03 Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024

Business Summary

Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.

Number of employees: 357

Sales per Business

USD in Million2022Weight2023Weight Delta
Ostoarthritis Pain Management
61.2 %
98 62.7 % 102 61.2 % +4.13%
Joint Preservation and Restoration
32.9 %
50 32.3 % 55 32.9 % +8.88%
Non-Orthopedic
5.9 %
8 5.1 % 10 5.9 % +24.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
73.9 %
119 76.3 % 123 73.9 % +3.34%
Other
13.1 %
16 10.5 % 22 13.1 % +32.61%
Europe
13.0 %
21 13.2 % 22 13.0 % +5.26%

Managers

Managers TitleAgeSince
Cheryl Blanchard CEO
 Chief Executive Officer 59 31/18/31
Michael Levitz DFI
 Director of Finance/CFO 50 10/20/10
Anne Nunes COO
 Chief Operating Officer 55 01/21/01
Mira Leiwant CTO
 Chief Tech/Sci/R&D Officer - 14/19/14
Steven Ek CTO
 Chief Tech/Sci/R&D Officer - 29/20/29
Mark Namaroff IRC
 Investor Relations Contact 60 -
Lisa Funiciello HRO
 Human Resources Officer - 01/22/01
David Colleran LAW
 General Counsel 52 04/20/04
James Chase SAM
 Sales & Marketing - 06/18/06
Ian McLeod AUD
 Comptroller/Controller/Auditor - 01/21/01

Members of the board

Members of the board TitleAgeSince
Susan Vogt BRD
 Director/Board Member 70 23/18/23
Sheryl Conley BRD
 Director/Board Member 63 28/21/28
Cheryl Blanchard CEO
 Chief Executive Officer 59 31/18/31
John Henneman CHM
 Chairman 62 03/20/03
Glenn Larsen BRD
 Director/Board Member 70 17/15/17
Gary Fischetti BRD
 Director/Board Member 63 13/23/13
Jeffery Thompson BRD
 Director/Board Member 58 18/11/18
Stephen Richard BRD
 Director/Board Member 61 03/20/03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 15,016,456 14,388,223 ( 95.82 %) 188,000 ( 1.252 %) 95.82 %

Shareholders

NameEquities%Valuation
Trigran Investments, Inc.
14.61 %
2,139,054 14.61 % 54 M $
Caligan Partners LP
9.723 %
1,423,493 9.723 % 36 M $
BlackRock Advisors LLC
9.154 %
1,340,229 9.154 % 34 M $
Caligan Partners LP
7.386 %
1,081,360 7.386 % 27 M $
Dimensional Fund Advisors LP
5.611 %
821,452 5.611 % 21 M $
Vanguard Fiduciary Trust Co.
5.219 %
764,045 5.219 % 19 M $
Renaissance Technologies LLC
3.854 %
564,329 3.854 % 14 M $
Boothbay Fund Management LLC
3.480 %
509,522 3.480 % 13 M $
Morgan Stanley Investment Management, Inc.
3.313 %
485,093 3.313 % 12 M $
The Capital Management Corp.
2.428 %
355,534 2.428 % 9 M $

Company contact information

Anika Therapeutics, Inc.

32 Wiggins Avenue

01730, Bedford

+781 457 9000

http://www.anikatherapeutics.com
address Anika Therapeutics, Inc.(ANIK)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Anika Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
26.49 USD
Average target price
30.33 USD
Spread / Average Target
+14.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ANIKA THERAPEUTICS, INC. Stock Anika Therapeutics, Inc.
+16.90% 388M
CSL LIMITED Stock CSL Limited
-3.93% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-16.48% 31.47B
UCB Stock UCB
+55.07% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.58% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.62% 8.84B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-1.75% 7.93B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ANIK Stock
  4. Company Anika Therapeutics, Inc.